Clinical Trials Directory

Trials / Unknown

UnknownNCT02638714

Treatment of Optic Neuropathies Using Autologous Bone Marrow-Derived Stem Cells

Treatment of Optic Neuropathies Using Autologous Bone-Marrow Derived Clusters of Differentiation (CD) 34+, 133+, and 271+ Stem Cells: A Pilot Study

Status
Unknown
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Stem Cells Arabia · Academic / Other
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Not accepted

Summary

A single arm, single center trial to assess the safety and efficacy of restoring function in damaged optic nerves using autologous purified populations of bone-marrow derived stem cells (BM-SCs) through a 24 month follow up period.

Detailed description

Optic nerve atrophy (ONA) is a condition defined as a damage to the optic nerve that harmfully affects central and peripheral vision. ONA may occur as a result of optic neuritis, compression by tumors or aneurysms, toxic and nutritional neuropathies, trauma, or as a secondary complication to other systemic diseases such as diabetes. Symptoms of ONA vary diversely, but mainly include blurred vision and a reduction in optic sharpness and color visualization. ONA is irreversible process, and current medical strategies focus on finding the underlying cause, and trying to prevent further vision loss and protect the other healthy eye. This is a Single arm, Single Center trial to assess the safety and efficacy of purified adult autologous bone marrow derived CD34+, CD133+, and CD271+ stem cells through a 24 month follow-up period. The combination of these three cell types was based on their diverse potentialities to differentiate into specific functional cell types to regenerate damaged optic nerves and supporting issues and vasculature, and the availability of clinical-grade purification system (CliniMACS) and Microbeads to purify the target cell populations in clinically-approved methods. Anticipated outcomes of this study are defined in an overall improvement of vision, restoration of functions to damaged optic nerves, and improvement in quality of life of patients.

Conditions

Interventions

TypeNameDescription
BIOLOGICALStem CellsIntervention: Transplantation of autologous purified stem cells

Timeline

Start date
2013-04-01
Primary completion
2021-09-01
Completion
2021-10-01
First posted
2015-12-23
Last updated
2020-03-17

Locations

1 site across 1 country: Jordan

Source: ClinicalTrials.gov record NCT02638714. Inclusion in this directory is not an endorsement.